<SEC-DOCUMENT>0000950103-21-011194.txt : 20210727
<SEC-HEADER>0000950103-21-011194.hdr.sgml : 20210727
<ACCEPTANCE-DATETIME>20210727073428
ACCESSION NUMBER:		0000950103-21-011194
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20210727
FILED AS OF DATE:		20210727
DATE AS OF CHANGE:		20210727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AC Immune SA
		CENTRAL INDEX KEY:			0001651625
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37891
		FILM NUMBER:		211115916

	BUSINESS ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
		BUSINESS PHONE:		41 21 345 91 21

	MAIL ADDRESS:	
		STREET 1:		EPFL INNOVATION PARK, BUILDING B
		CITY:			1015 LAUSANNE
		STATE:			V8
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>dp155090_6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K<BR>
</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt"><B>REPORT OF FOREIGN
PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 6.85pt; text-align: center; text-indent: -6.85pt">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the month of July, 2021</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<HR SIZE="2" NOSHADE ALIGN="CENTER" STYLE="width: 21%; color: black">

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-37891</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 28pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AC IMMUNE SA</B></P>

<P STYLE="font: 28pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified in its
charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EPFL Innovation Park</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Building B</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1015 Lausanne, Switzerland</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover of Form&nbsp;20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 66%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 20-F</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">X</P>
</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Form 40-F</FONT></TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; width: 14%">
</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation&nbsp;S-T&nbsp;Rule&nbsp;101(b)(1):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 66%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; width: 14%">
</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">X</P>
</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark if the registrant is submitting
the Form 6-K in paper as permitted by Regulation&nbsp;S-T&nbsp;Rule&nbsp;101(b)(7):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="width: 66%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 29%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Yes</FONT></TD>
    <TD STYLE="border-bottom: Black 0.5pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; width: 14%">
</TD>
    <TD STYLE="width: 15%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 28%; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">No</FONT></TD>
    <TD STYLE="width: 14%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: Black 0.5pt solid">X</P>
</TD></TR>
  </TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 3.5pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">On July
27, 2021, the Company issued a press release regarding its entry into an Asset Purchase and Contribution in Kind Agreement, two Convertible
Note Agreements and the related agreements described herein, a copy of which is attached as Exhibit 99.1 to this Report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Asset Purchase and Contribution in Kind Agreement
(&ldquo;Asset Purchase Agreement&rdquo;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the Asset Purchase Agreement, the
Company will acquire, on the Closing Date, the program portfolio of therapeutics targeting alpha-synuclein (a-syn), notably PD01, a clinically-validated
active vaccine candidate for the treatment of Parkinson&rsquo;s disease (the &ldquo;Transferred Assets&rdquo;) from Affiris AG (the
&ldquo;Seller&rdquo;). The Transferred Assets comprise of patents, patent applications, know how, trademarks and copyrights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company will acquire the Transferred Assets
and USD 5 million in cash in exchange for 7,106,840
shares of the Company at closing based on a price of USD 8.26 per common share, for a total value of USD 58.7 million. This represents a 10.7% premium to the closing price
of the Company&rsquo;s shares as of July 23, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The acquisition is subject to customary regulatory
approval in Austria and expected to complete at the beginning of Q4 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B>Convertible Note Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Concurrently with the Asset Purchase Agreement,
the Company entered into two separate Convertible Note Agreements with entities affiliated with each of Athos Service GmbH and First Capital Partner GmbH (collectively,
the &ldquo;Investors&rdquo;), both of which entities are shareholders of Affiris. Each Convertible Note Agreement provides for the sale
of an unsecured subordinated Convertible Note of the Company with an aggregate principal amount of 12.5 million. The total net proceeds
to the Company are USD 25 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Convertible Notes are convertible into common
shares after the Closing Date of the Asset Purchase Agreement at any time at the option of the Investors or of AC Immune at a conversion
price of USD 8.26. These options are effective from the signing date of the Convertible Note Agreements until 10 calendar days prior
to the Repayment Date (&ldquo;Conversion Period&rdquo;). If the Convertible Notes are not converted during the Conversion Period, they
shall be repaid on the Repayment Date, which is July 26, 2022. The Convertible Notes do not permit partial settlement and do not bear
interest.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><FONT STYLE="background-color: white">This Report
on Form 6-K (excluding Exhibit 99.1&nbsp;herewith) is incorporated by reference into the Registrant's registration statement on Form F-3
(File Nos. 333-227016, 333-249655 and 333-255576) and Form S-8 (File No. 333-233019).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt"><B>AC IMMUNE SA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Andrea Pfeifer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 27%">&nbsp;</TD>
    <TD STYLE="width: 19%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt">Andrea Pfeifer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><BR>
</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Joerg Hornstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 27%">&nbsp;</TD>
    <TD STYLE="width: 19%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt">Joerg Hornstein</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Date: July 27, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 8%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Exhibit
Number</B>&nbsp;</P></TD>
    <TD STYLE="padding-left: 4pt; width: 92%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 0.5pt solid"><B>Description</B>&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 12pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="padding-left: 4pt; font-size: 12pt"><FONT STYLE="font-size: 10pt">Press Release dated July 27, 2021</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <DIV STYLE="text-align: center; margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">3<P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dp155090_ex9901.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; color: gray"><B><IMG SRC="image_001.jpg" ALT="" STYLE="height: 46.2pt; width: 148.2pt">&nbsp;</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AC Immune Announces Strategic Acquisition of
Industry-leading Parkinson&rsquo;s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH</B></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>All-stock transaction maintains AC
Immune&rsquo;s strong cash position</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>USD 25 million private placement
led by premier investor Athos Service GmbH</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>Transactions expand and accelerate
AC Immune&rsquo;s therapeutic development in Parkinson&rsquo;s disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>AC Immune to immediately launch clinical
development of acquired vaccine into an adaptive, biomarker-based Phase 2 study in Parkinson&rsquo;s disease</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><I>Conference call scheduled today at
8:30 am ET / 2:30 pm CET</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&nbsp;</P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Lausanne, Switzerland,
July 27, 2021</B> &ndash; AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative
diseases, today announced that it is acquiring Affiris&rsquo; portfolio of therapeutics targeting alpha-synuclein (a-syn), notably Affiris
PD01, a clinically-validated active vaccine candidate for the treatment of Parkinson&rsquo;s disease, as well as cash. The all-stock
asset acquisition is valued at USD 58.7 million. AC Immune&rsquo;s cash position, as well as the Company&rsquo;s investor base, is also
being strengthened by a total of USD 30 million in gross proceeds stemming from the asset acquisition and a parallel financing that are
adding Athos Service GmbH (Str&uuml;ngmann family office), <FONT STYLE="color: Blue"><U>First Capital Partner GmbH (Egger Family Office</U></FONT>)</FONT><SUP>1
</SUP><FONT STYLE="font-size: 10pt">and <FONT STYLE="color: Blue"><U>MIG Fonds</U></FONT><SUP>2</SUP>, the lead investors in Covid-19
vaccine innovator BioNTech SE, as new AC Immune shareholders. </FONT></P>

<P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the agreement, AC Immune is
acquiring all of Affiris&rsquo; assets and underlying intellectual property related to active vaccine candidates targeting a-syn and USD
5 million in cash for 7.1 million shares based on a price of USD 8.26 per common share. This share price represents a 10.7% premium compared
to the closing price of AC Immune shares as of July 23, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concurrent with the asset acquisition, AC Immune
announced a private placement transaction with a select group of investors led by Athos Service GmbH with additional participation from
First Capital Partner GmbH. Gross proceeds from the private placement will be USD 25 million, based on the same financial terms as for
the acquisition of the therapeutic anti-a-syn portfolio. Another lead BioNTech and Affiris investor, MIG<FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><SUP>o</SUP></FONT>Fonds,
is also becoming a new AC Immune shareholder via its prior ownership of the anti-a-syn assets acquired. In total, AC Immune is issuing
10.1 million shares in conjunction with the asset acquisition and related financing, in exchange for the aforementioned anti-a-syn assets
valued at USD 53.7 million and USD<FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><SUP>o</SUP></FONT>30 million
in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">With the support of their new premier investors,
who are highly experienced in active vaccination, AC<FONT STYLE="font-family: Times New Roman, Times, Serif; color: white"><SUP>o</SUP></FONT>Immune
will leverage its own extensive expertise in vaccine development and neurodegenerative diseases to immediately launch clinical development
of ACI-7104, the optimized formulation of PD01, into an adaptive, biomarker-based Phase 2 study. This trial will evaluate an initial dose-response
of the optimized formulation focusing on immunogenicity against a-syn and pathological a-syn species. Additionally, progression of motor
and non-motor symptoms of Parkinson&rsquo;s disease will be monitored, together with digital, imaging and fluid biomarkers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->/4</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Michael Motschmann, General Partner of MIG
Fonds, added:</B> &quot;AC Immune is uniquely positioned to successfully advance the industry-leading anti-a-syn vaccine program developed
by Affiris and its investors. The program will benefit from AC Immune&rsquo;s deep expertise in precision medicine and active vaccination
approaches for neurodegenerative diseases. We are thrilled to be joining their high-quality investor base and believe this transaction
will be of great benefit to our shareholders and the millions of patients suffering from neurodegenerative diseases around the world.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Thomas Str&uuml;ngmann, Co-Founder of Athos
Service GmbH, commented: </B>&ldquo;We have learned from Covid-19 that collaboration can accelerate the development of safe and efficacious
vaccines that can be deployed broadly to deliver highly effective protection for very large populations. This is why we strongly endorse
this transaction with AC Immune, a global leader in vaccine development in neurodegeneration with an impressive precision medicine pipeline
and record of execution. We look forward to working with the Company to potentially translate what has been done for infectious diseases
to neurodegenerative diseases like Parkinson&rsquo;s and Alzheimer&rsquo;s.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Prof. Andrea Pfeifer, CEO of AC Immune SA,
commented: </B>&ldquo;We believe very strongly that active vaccination will play an important role in the long-term management and possible
prevention of neurodegenerative diseases. By acquiring a clinically validated vaccine program against a-syn, we are advancing AC Immune
to the forefront of Parkinson&rsquo;s disease drug development, with a wholly-owned a-syn portfolio that now covers a full spectrum of
treatment modalities addressing this well-characterized target.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;We are also proud to welcome three of the
foremost investors in vaccine development, the Str&uuml;ngmann Family&rsquo;s Athos Service, First Capital Partner GmbH and MIG Fonds,
to AC Immune. As the lead investors in BioNTech, they have a globally recognized track record of identifying and supporting successful
vaccine technologies. Their support of Affiris and now AC Immune serves as an endorsement of an active immunization approach for Parkinson&rsquo;s
disease, and provides key external validation for AC Immune&rsquo;s unmatched expertise in the development of vaccines for neurodegenerative
diseases.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Parkinson&rsquo;s disease is causally linked
to pathological aggregation and deposition of a-syn, a drug target that has been validated in clinical studies using monoclonal antibodies.
Affiris PD01 is a vaccine designed to generate a target-specific antibody response against pathological oligomeric a-syn. Randomized
Phase 1 results <FONT STYLE="color: Blue"><U>published in <I>The Lancet Neurology</I></U></FONT> showed that PD01 generated substantial,
long-lasting and boostable antibody responses against pathological forms of a-syn that were accompanied by target engagement and signals
of clinical efficacy. These data also showed that PD01 had a favorable safety and tolerability profile. This anti-a-syn vaccine complements
AC Immune&rsquo;s existing portfolio of clinical and preclinical candidates addressing a-syn, which includes an anti-a-syn antibody,
a small molecule aggregation inhibitor, and a first-in-class diagnostic imaging agent, which together may enable a precision medicine
approach to treating Parkinson&rsquo;s disease and other alpha-synucleinopathies. With this acquisition, AC Immune becomes a leader in
the development of therapeutics and diagnostics for Parkinson&rsquo;s disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AC Immune&rsquo;s expertise in active vaccine
development is based on its SupraAntigen<SUP>&reg;</SUP>-V vaccine platform, which has been shown to generate powerful, target-specific,
polyclonal antibody responses that are in the range of therapeutic monoclonal antibodies. Earlier this year, the Company reported highly
encouraging readouts from its ongoing Alzheimer&rsquo;s disease vaccine programs targeting <FONT STYLE="color: Blue"><U>phospho-Tau</U></FONT>
and <FONT STYLE="color: Blue"><U>pathological amyloid beta (Abeta</U></FONT>) including the most toxic oligomeric and pyroglutamate Abeta
species. With the recent accelerated approval of the passive immunotherapy Aduhelm&trade; based on Abeta biomarker data and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->/4</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">encouraging clinical results for the anti-Abeta
antibody donanemab that demonstrate the potential benefit of targeting pyroglutamate Abeta species, AC Immune is positioned to greatly
accelerate the potential time-to-market for its optimized Abeta vaccine. AC Immune is leveraging its extensive vaccine expertise to enrich
and accelerate the development of ACI-7104 for Parkinson&rsquo;s disease and other a-synucleinopathies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The acquisition is subject to customary regulatory
approval in Austria and expected to complete at the beginning of Q4 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Conference Call Information </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AC Immune will hold a conference call today, July
27, 2021, at 8:30 am ET / 2:30 pm CET. Interested participants and investors may access the conference call by dialing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
877-407-0792 (U.S.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
+1 201-689-8263 (International)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Conference ID: 13721912 </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A live webcast will be accessible via the <FONT STYLE="color: Blue"><U>Events
</U></FONT>section of the Company&rsquo;s website. An archive of the webcast will be available for 90 days beginning at approximately
9:30 am ET / 3:30 pm CET, today, July 27, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About AC Immune SA </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AC Immune SA is clinical-stage biopharmaceutical
company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer&rsquo;s disease,
Parkinson&rsquo;s disease, and NeuroOrphan indications driven by misfolded proteins. The Company&rsquo;s two clinically validated technology
platforms, SupraAntigen<SUP>&reg;</SUP>&nbsp;and Morphomer<SUP>&reg;</SUP>, fuel its broad and diversified pipeline of first- and best-in-class
assets, which currently features ten therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune
has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member
of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance
its proprietary programs and &gt;$3 billion in potential milestone payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SupraAntigen<SUP>&reg;</SUP> and Morphomer<SUP>&reg;</SUP>
are registered trademarks of AC Immune SA in the following territories: AU, CH, EU, JP, and GB. Morphomer<SUP>&reg;</SUP> is also a registered
trademark of AC Immune SA in CN and NO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>References:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify"><FONT STYLE="color: Blue"><U>https://firstcapitalpartner.de/index.html</U></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify"><FONT STYLE="color: Blue"><U>https://www.mig-fonds.de/home.html</U></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>For further information, please contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Media Relations</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Saoyuth Nidh</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AC Immune SA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: +41 21 345 91 34</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Email: <FONT STYLE="color: Blue"><U>saoyuth.nidh@acimmune.com</U></FONT></FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD>
    <TD STYLE="width: 54%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Investor Relations</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Yves Kremer, Ph.D.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">AC Immune SA</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: +41 21 345 91 90</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Email: <FONT STYLE="color: Blue"><U>yves.kremer@acimmune.com</U></FONT></FONT></P>
    <P STYLE="font: 11pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->/4</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page --><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;<IMG SRC="image_002.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. Media</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Katie Gallagher</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LaVoie Health Science</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: +1 617 792 3937</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: <FONT STYLE="color: Blue"><U>kgallagher@lavoiehealthscience.com</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 54%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>U.S. Investors</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chris Maggos</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LifeSci Advisors</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: +1 917 809 0814</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: <FONT STYLE="color: Blue"><U>chris@lifesciadvisors.com</U></FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD></TR>
  </TABLE><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-looking statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release contains statements that constitute
&ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future
operating, financial or business performance or AC Immune&rsquo;s strategies or expectations. In some cases, you can identify these statements
by forward-looking words such as &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;expects,&rdquo;
&ldquo;plans,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;predicts,&rdquo; &ldquo;projects,&rdquo;
&ldquo;potential,&rdquo; &ldquo;outlook&rdquo; or &ldquo;continue,&rdquo; and other comparable terminology. Forward-looking statements
are based on management&rsquo;s current expectations and beliefs and involve significant risks and uncertainties that could cause actual
results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties
include those described under the captions &ldquo;Item 3. Key Information &ndash; Risk Factors&rdquo; and &ldquo;Item 5. Operating and
Financial Review and Prospects&rdquo; in AC Immune&rsquo;s Annual Report on Form 20-F and other filings with the Securities and Exchange
Commission. These include: the impact of Covid-19 on our business, suppliers, patients and employees and any other impact of Covid-19.
Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in
light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements
are qualified in their entirety by this cautionary statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: right; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->/4</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +E"3H# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIK.J#+,%^II-I*[ =15=
MKV!?XBWT%0MJ0_AC)^IKDJ9AAH;S7Y_D4H2?0O45F'493T513#?3G^,#\!7-
M+.<,MKOY?\$KV4C6HK'-W.?^6AH^U3_\]&K+^VZ/\K_ ?LF;%%9 NYQ_RT/Y
M"G"^G'5@?J*I9UAWNFOZ]0]E(U:*SEU%_P"*-3]#BIDU"(_>5E_6NF&9X6?V
MK>NA+IR1;HJ-)XI/N."?2I*[8SC-7B[HBU@HHHJ@"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **R;_ ,3Z)IN1=ZG;(PZHK[F'_ 5R:YV\^*>A
MP9%O%=7)]50*OZG/Z5#G%;LZ:6#Q%7X(-_+_ (8[BBO++GXN7#'%KI,2>\LI
M;] !65/\4/$,N=GV2'_KG#G_ -")J'7@CMADF+ENDO5_\.>T45X3)\0?$\O7
M4RHSG"PQC_V6H&\:^)';)U>XS[8'\A4_68]C=9!B.LE^/^1[[17@2>-O$B'(
MU>?\<'^8JQ%\0O$\>!_:6X#LT,9_7;FCZS'L#R#$=)+\?\CW6BO&H/BGKT7^
MMBLYA_M1D']"*V;3XN(>+S26'^U#+G]"/ZU2KP9SSR7&1VBGZ/\ X8],HKE+
M#XB^'+W :Z>U<_PW$97]1D?K72V]U;WD0EMIXIXST>)PP_,5HI)[,X*N'JTO
MXD6O5$U%%%48A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "E5F1@RDJP.00<$&DHH ]I\!^,!KUI]AO7']HPKU/\
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MI\+5]K2C(]2E+F@F%%%%=!H%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% '7?#G6#IGBB.!VQ!>CR6';=_"?SX
M_P"!5[=7S+'(\,J21L5=&#*P[$=*^C=)OUU32+2^3 $\2N0.Q(Y'X'(KKPTM
M'$^6S_#\LXUEUT?R_P" 7:***Z3YX**** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^Y/^_+?X5T5O/'=6\<\+!HI%#HP[@C(H DHHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9E[<^8WEH?
MD'7W-6+VX\M-BGYV_05F5\_F^-_YAX/U_P O\S:G#JPJ6"$SRA1T[GT%1 $D
M <DUL6T @B _B/+&O/R[!_6:NOPK?_(N<N5$JJ$4*HP!TI:**^O225D<P444
M4P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EJ/^
MJ0_[59U:6H_ZE/\ >K-KY+-_]Z?HOR.FG\(57O+M+.V:5^W"CU-3LP52S$
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M#^(KC*Z[X?:1]OUS[9(N8;,;^>[G[OY<G\!2 ]84DJ"1@D<CTI:**0PHHHH
M**** "BBB@ HHHH *\1\6?\ (UZE_P!=C_(5[=7B/BS_ )&O4O\ KL?Y"F@,
M:O4/AE_R!;S_ *^/_917E]>H?#+_ ) MY_U\?^RBAB.WHHHI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[3O^OJ+_ -"%4:NZ0@DUJP0YPUQ&#C_>%"W(J_!+T?Y,^CZ***]0_. HHHH
M**** "BBB@ HHHH **** "N+^(VJ?9=&CL$;$ETV6_W%Y_GC]:[2O%?&&J?V
MKXCN9%;,,1\F/Z+W_$Y/XTT!A5T'@[14UK75BG7=;1(9)1Z]@/S(_*N?KUCX
M=Z7]CT%KQUQ)=MN'^X.!_4_C0Q'F&H64FG:C<6<OWX9"A/KCH?QZU6Z'(KN?
MB3IGDZE!J2+\EPNR0_[:]/S&/^^:X:F![EX<U0:OH-K=ELR%=LO^^.#_ (_C
M6K7FOPUU7R[NYTN1OEE'FQ@_WAU'XC'_ 'S7I52,**** "BBB@ HHHH ****
M "BBN6\9^)QHEG]FM6'VZ=?E/_/-?[WU]/\ ZU %/QAXS&F;]/TUU:\/$D@Y
M$7L/]K^5>7N[RR-)(S.['+,QR2?4FD9F=V=V+,QR23DDTE4(*FM;2XOKA8+6
M%YI6Z(@R:V?#?A2[\03;QF&S4X>8CK[+ZG^5>LZ5HUCHML(+*$(/XG/+.?4F
ME<#AM(^&LKA9=6N?+'7R82"WXMT_+/UKL]/\.:1I@'V6QB#C_EHXW-^9YK5H
MI#"BBB@ HHHH *KW5C:7T>R[MH9U])$#?SJQ10!QVI_#K2KL,]D\EG)V .]/
MR//Y&MGPUH:Z!I"6A97E+%Y74<,3_P#6P*V** "BBB@ HHHH **** "BBB@
MHHHH *\1\6?\C7J7_78_R%>W5XCXL_Y&O4O^NQ_D*: QJ]0^&7_(%O/^OC_V
M45Y?7J'PR_Y MY_U\?\ LHH8CMZ***0PHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;511P!4M%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>(^+/^1KU+_KL?Y"O;J\1\6?\ (UZE_P!=C_(4T!C5ZA\,O^0+>?\
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MFGN2/^>4>!_X]BL:X^*':WTO_@4DW] /ZT >B45Y9)\3-68GR[6R0>ZL2/\
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MW+O_ +]C_&C_ (6/H?\ <N_^_8_QH ZZBH+*[CO[*&[AW>7,@==PP<'UJ>@
MHHHH **** "BBJ5[J^G:=G[7>P0D?PNXW?EUH NT5R=U\1-#MR1$;BY/_3./
M _\ 'L5D3_% <BWTOZ-)-_0#^M 'H=%>6R?$S52?W=G9J/\ :5C_ .S"H/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4%W+Y4!P?F;@5/65?2^9/M'1./QK@S+$>PP[:W>B_KT+A&[*U%%%?'
M'236L?F7*#L#DUL5GZ<G+O\ @*T*^KR>ER8?F_F?_ .>J[R"BBBO5,PHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J6HR8C
M6,=2<GZ5=KGM6O?*BFN,]!A/KVKR\WQ'LL/RK>6GRZFM&#G-)',ZY=_:+TQ*
M?DB^7\>]9E*2222<D]325\@?54X*$5%= HHHI%A1110 4444 %%%% !1110
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M_"JU%;/A72_[7\16MNRYB5O,E]-J\\_7@?C5"/4_">E_V3X<M8&7$KCS9?\
M>;G]!@?A6W114C"N%^)6F>=I]OJ2+\T#>7(1_=;I^1_]"KNJJZE8QZEIMS92
M?=FC*9]#V/X'F@#P*NC\$:I_9GB2$.V(;G]R^>G/0_GC\S6!/#);W$D$J[9(
MV*,/0@X-,!*D$$@CD$50CZ&HK,\/:F-8T*UO,Y=DVR>SC@_KS^-:=2,****
M"BBB@ JM?WD>GZ?<7DOW(8RY'K@=*LUQOQ'O_L^@Q6BMAKJ4 CU5>3^NV@#R
M^YN)+NZEN)FW22N78^I)S45%6=/LWU#4;>SC^_-($!],GK^%4(])^'6BBTTQ
M]3E7]]<_+'GM&#_4_P A7:U';P1VUO%!$NV.) BCT &!4E2,**** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KQ'Q9_P C7J7_
M %V/\A7MU>(^+/\ D:]2_P"NQ_D*: QJ]0^&7_(%O/\ KX_]E%>7UZA\,O\
MD"WG_7Q_[**&([>BBBD,*9--%;Q-+-(D<:C+.YP /<T^N=\=?\B;?_\ ;/\
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MSV-W'=6TACFC;<K#M2 ^@:*Q_#>O1>(-*6Y4!)D^2:,?PM[>Q[5L4AA1110
M5S/C[_D4;G_?C_\ 0A735S/C[_D4;G_?C_\ 0A0!X]5C3_\ D)6O_79/YBJ]
M6-/_ .0E:_\ 79/YBJ$>_P!%%%2,**** "BBB@ HHHH *KZA_P @VZ_ZXO\
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M>Y/N3S5RO>ITU!'QN88V6+J\WV5LOZZL****T. **** "BBB@ HHHH ****
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M_D*]NKQ'Q9_R->I?]=C_ "%- 8U>H?#+_D"WG_7Q_P"RBO+Z]0^&7_(%O/\
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M[3^"/HOR1R/<****L04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3T444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>(^+/^1KU+_KL?Y"O;J\1\6?\ (UZE_P!=C_(4T!C5ZA\,O^0+>?\
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MF*KU8T__ )"5K_UV3^8JA'O]%%%2,**** "BBB@ HHHH *KZA_R#;K_KB_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI:*QO$GB"/P[IRW+0^<[N$2/?MSW)S@]*D9LT5YY_P +2_Z@W_DU_P#84?\
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MDE%%%>X8A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(S*BEF.
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M%%>J?+!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%8/C'6!HGAF[N%;;-(ODPXZ[VXR/H,G\*3=E=FE*G*K-0CNW8\<\7
M:H-7\47UTK;HM_EQ^FU>!CZXS^-8E%%>8W=W/T.G35."A'9*PJJSNJ(I9F.
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M/Y5JU(PHHHH \W^*'_'SIO\ N2?S6N KO_BA_P ?.F_[DG\UK@*:$=5\/?\
MD:X_^N+_ ,J]=KR+X>_\C7'_ -<7_E7KM#&%%%%( HHHH **** "BBB@#ROX
ME_\ (QV__7HO_H;UQE=G\2_^1CM_^O1?_0WKC*8CM_AE_P AN[_Z]O\ V85Z
MA7E_PR_Y#=W_ ->W_LPKU"AC"BBBD!YO\4/^/G3?]R3^:UP%>B?%%/\ D%R
M?\]03_WSC^M>=TT(**NZ5I=QK&H)96Q02N"1O.!P,UT/_"N-<_OVG_?P_P"%
M,#D:*Z[_ (5QKG]^T_[^'_"C_A7&N?W[3_OX?\*0'(T5UW_"N-<_OVG_ '\/
M^%'_  KC7/[]I_W\/^% '(T5UW_"N-<_OVG_ '\/^%'_  KC7/[]I_W\/^%
M'(T5UW_"N-<_OVG_ '\/^%'_  KC7/[]I_W\/^% '(T5UW_"N-<_OVG_ '\/
M^%'_  KC7/[]I_W\/^% '(UV?PT_Y&.X_P"O1O\ T-*B_P"%<:Y_?M/^_A_P
MKH_!OA/4-!U6:ZO&A*O 8U\MR>2P/I[4 =M1112&%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXTF?'^S_ .A"K]9^MY_LJ7ZK_,4,UH?Q8^J.3HHHK,^A"BBB@ HHHH ****
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MR*-S_OQ_^A"O'J]A\??\BC<_[\?_ *$*\>IH18T__D)6O_79/YBO?Z\ T_\
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MWL6::[J@RS #WK.DU"1N$ 0?F:JL[.<LQ)]Z\NOG5*.E)7?W+_,T5)]2_+J
M'$2Y/J:HO(\C;G8DTVBO#Q&,K8A^^].W0VC%1V"BBBN484444 %%%% !5'61
MG29_P_\ 0A5ZJNI+OTVX'^P3^7-!I2=JD7YHXVBBBLSZ(**** "BBB@ HHHH
M ***Q=>U+[/%]EB;]ZX^8C^%?_KUK1I2JS4(E0@YRLC+UO4?MESY<9_<QG _
MVCZUET45]/2IQIP4([(]2,5%61Z5\(H@;C5I>,JL2_F6_P *]2KS3X1;?)U;
M&-^Z+/TP^/ZUZ77IT/@1\5G#OC)_+\D%%%%:GF!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 445Q/Q$\4#2--_LZUDQ>W2X)'6./
MH3]3T'XU,I**NS;#T)XBJJ<-V<1\0/$G]MZT;:W?-E:$HA!X=_XF_H/I[UR%
M%2002W5Q'!!&TDLC!411RQ/05YTI.3NS[ZA1AAZ2IQV7]7-;POX?E\1ZU%9I
MN6%?GGD'\"#K^)Z"O?;>WBM+:*W@01Q1*$11T '2L7PCX;C\-Z.L!PUU+A[B
M0=V]![#_ !/>M^NZC3Y%KN?'YICOK56T?A6W^?\ 70****U/+"BBB@ HHHH
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MX9?\@6\_Z^/_ &45Y?7J'PR_Y MY_P!?'_LHH8CMZ***0PI" 001D'J#2T4
M>":K9'3M6N[,@_N9649[C/!_+%4Z[SXDZ08KR#58U^24>7*0.C#H?Q''_ :X
M.J$>L_#S4Q>>'_LC-^]M'*XSSM/(/\Q^%==7A_AO7'T'5X[H M"WR3(/XE/]
M1UKVNVN8;RVCN+>19(I%W*R]"*3&2T444@"BBB@ HHHH *X#XF:F%M[73$/S
M.WG2#T X7\SG\J[34M2MM)L)+RZ?;&@Z=V/8#W->(:MJ<VKZG/?3_?E;A1T4
M=@/H*: I5N>#['[?XHLD(RD;^<WT7G^>!^-8=>F_#;2#!93ZI*I#3GRXLC^
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M.HH&M#@R,'!HJSJ$7DZA.G^V2/H>:K5!]'&7,DPHHHI%!1110 445%<7$=K
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M&GADMKB2"5=LD;%&'H0<&OH.O)OB'I?V+7Q=HN(KM=WMO'#?T/XTT!R->O\
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MBBB@ HHHH **** "BBB@ KQ'Q9_R->I?]=C_ "%>W5XCXL_Y&O4O^NQ_D*:
MQJ]0^&7_ "!;S_KX_P#917E]>H?#+_D"WG_7Q_[**&([>BBBD,*YWQU_R)M_
M_P!L_P#T8M=%7.^.O^1-O_\ MG_Z,6@#QJK&G_\ (2M?^NR?S%5ZL:?_ ,A*
MU_Z[)_,50CW^BBBI&%%%% !1110 4444 1W'_'M+_N'^5?/E?0=Q_P >TO\
MN'^5?/E-""O;O"7_ "*FF_\ 7$?S->(U[=X2_P"14TW_ *XC^9H8&S1112&%
M%%% !1110 4444 >(^+/^1KU+_KL?Y"L:MGQ9_R->I?]=C_(5C50CU#X9?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3H,]UK@OL\W_ #QD_P"^37T'13N!Y+\/XI$\4H6C=1Y3\D8[5ZU112 ****
M"BBB@ HHHH **** /+?B3%(_B*W*(S#[(O(&?XWKCOL\W_/&3_ODU]!T4[@>
M8_#2*1-:NRZ,H^S]QC^(5Z=112 **** "BBB@ J&[L[>^MVM[J%)HFZJXR*F
MHH \]U?X:JS-+I-R%[^1-T_!O\?SKC;_ ,/:MIA/VNPF11_&%W+_ -]#BO=*
M*=P/GBBO>[G2=.O"3<V%M*Q[O$I/YXK/?P=X?D.6TR(?[I9?Y&BXCQ2BO9AX
M&\. @_V;T]9I/_BJE7P=X?0Y&F1?B6/\S1<#Q2I(;>>Y?9!#)*W]U%+']*]R
MAT'2(#F+2[-2._DKG\\5?1$C4*BJJCH%&!1<9XU9>"M>O<$6+0(?XIR$Q^!Y
M_2NITWX9PH5?4KQI3WC@&T?]]'D_D*[ZBBX%33]+LM*@\FQMDA0]=HY;ZGJ?
MQJW112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#^H_ESZUW=>C&2DKH^!Q.'GAZCISW7]7"BBBJ, HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MI&4.I5AE2,$'N*6K=O9-)AI,JOIW-;4,/4KRY*:NQ.2CJSSC7Y(]"E(ERP;F
M(#JPKAKV_FOYM\K<#[JCHM>Z>*O#,'B'13:J%CN(LM;O_=;T/L>_Y]J\'N;:
M:SN9+>XC:.:)BKHW4$5[U'+XX75ZOO\ Y'U&4XFG7IW^TM_\R*BBBN@]<***
M* "BBB@ HHHH **** )()Y;6XCG@D:.6-@R.IP5([U[-X.\<V^O1I9WK+#J2
MC&.BS>Z^_M^7MXK2JS(P9258'((."#5TZC@]#BQN!IXN%I:-;/\ KH?3=%>3
M>&?B;/:!+76U:XA' N5YD7_>'\7UZ_6O3M/U.QU:V%Q874=Q%ZH>GL1U!]C7
M="I&>Q\=BL#6PKM46G?H6Z***LXPHHHH **** "BBB@ HI&944LQ"J!DDG %
M<OJ_Q T'2@R+<_;)Q_RSM_F'XMT_6DY*.YK2H5*SY:<6V=36%KWB[2/#Z%;J
M</<8XMXOF<_7T_&O,=;^(^LZINBM6%A;GC;"<N1[OU_+%<>S%F+,26)R2>IK
MFGB%M$]W"Y#)^]B';R7^?^1T_B/QUJFO[H0WV2R/'D1-]X?[3=_T'M7+T5;T
M[3+S5KQ+2QMWFF;LHX ]2>@'N:YFW)ZGT5.E2P\+02C%%0 D@ 9)[5Z1X/\
MATT_EZAKD96+[T=H>"WN_H/;\ZZ/PIX!L]""7=YLNM0ZAL?)%_N@]_?^5=C7
M52H6UD?.YAG+E>GA]N_^7^8U$6-%1%"HHPJJ, #T%.HHKI/G0HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** &R(LB%&&0:R)X&@?!Z'H?6MFF21K*A1QD?RKS\?@8XJ-UI);?Y,N$
M^4Q**FGMW@;!Y4]&J&ODJE.5.3A-6:.E.^J"BBBH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ***4 DX R?04 )3XXGE;:BDFK4%@S?-
M*=H]!UJ^D:QKM10!7KX3*:E7WJONK\?^ 9RJ);%>WLDBPS_,_P"@JU117TE&
MA3HQY*:LC!MO<*XGQWX,&N0'4+! -1C7YE''G*.W^\.WY>E=M15RBI*S-</B
M)X>HJE-ZH^971HW9'4JZG#*PP0?0TVO9/&W@5-;#:AIJK'J 'SIT$_\ @WO^
M?K7CTT,MO,\,T;1RH=K(PP0?0BN"I3<'9GV^"QM/%PYH[]5V_P" ,HHHJ#M"
MBBB@ HHHH **** "BBB@ J>TO;JPG$]I<2P2CH\;%3^E044":35F=SIGQ1UB
MT"I?10WJ#N1Y;_F./TKJK/XIZ). +F&ZMF[Y0.OY@Y_2O'**UC6FNIYM;*,)
M5UY;/RT_X![[!XV\-W ^35X!_P!=,I_Z$!5L>)=!(!&M:=SZW2#^M?.]%7]9
MEV.-\/T>DW^!]#OXGT%!DZUIY_W;A#_(U1G\>>&;<?-JB.?2-&;^0KP:BAXF
M78<>'Z"WFW]Q[!=_%71H<BVM;NX;L2 BG\2<_I7.7_Q5U>XRME:V]HIZ$YD8
M?B<#]*X*BH=:;ZG72RC"4]>6_KJ:&HZ[JFKMF_OYYQ_<9L*/HHX'Y5GT45DV
MWN>C&$8*T59!16IHOAW4]?G\NPMF=0<-*W")]3_3K7JOASX=Z;HY2XO<7MX.
M07'[M#[+W^I_2M(4I3V.+%YC0PJM)WEV6_\ P#A/#/@'4==*7%R&M+ \^8P^
M:0?[(_J>/K7KVCZ)I^A6@MK"W6-?XFZLY]6/>M"BNR%*,-CY/&9C6Q3M)VCV
M7]:A1116AP!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVEMY1_#(I&?<>H]ZK5SGN*2DKIZ!1110,**** "BBB@ HHHH **** "BBB@
MHHI55G8*H)8G  &2: $HKJ-)^'^OZIM8VOV2$_QW/R_^.]?TKOM&^&>CZ>5D
MOF:_F'9QMC!_W1U_$FM(T9R/.Q&:8:AHY7?9:_\  /*])T'4];E\O3[228 X
M9\81?JQX%>D:#\+K.UVS:Q-]JE'/DQDK&/J>K?I7?Q0Q6\2Q0QI'&@PJ(H
M]@*?73"A&.^I\_BLZKUO=I^ZOQ^__(C@@AMH4A@B2*)!A410 ![ 5)116YXS
M=]6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] ,8# 2(  A$! Q$!_\0
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M#?RIW'RNU[:$U%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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:444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
